Gyre Therapeutics (GYRE) filed a shelf registration statement with the US Securities and Exchange Commission Thursday covering the potential sale of up to $150 million of its securities from time to time in one or more offerings.
The statement covers common and preferred shares, debt securities, warrants, and units.
The company said it will use the net proceeds generated from any securities sale for development, manufacturing, and scale-up, as well as for working capital and general corporate purposes, among other things.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.